Genome-wide CIITA-binding Profile Identifies Sequence Preferences That Dictate Function Versus Recruitment
Overview
Authors
Affiliations
The class II transactivator (CIITA) is essential for the expression of major histocompatibility complex class II (MHC-II) genes; however, the role of CIITA in gene regulation outside of MHC-II biology is not fully understood. To comprehensively map CIITA-bound loci, ChIP-seq was performed in the human B lymphoblastoma cell line Raji. CIITA bound 480 sites, and was significantly enriched at active promoters and enhancers. The complexity of CIITA transcriptional regulation of target genes was analyzed using a combination of CIITA-null cells, including a novel cell line created using CRISPR/Cas9 tools. MHC-II genes and a few novel genes were regulated by CIITA; however, most other genes demonstrated either diminished or no changes in the absence of CIITA. Nearly all CIITA-bound sites were within regions containing accessible chromatin, and CIITA's presence at these sites was associated with increased histone H3K27 acetylation, suggesting that CIITA's role at these non-regulated loci may be to poise the region for subsequent regulation. Computational genome-wide modeling of the CIITA bound XY box motifs provided constraints for sequences associated with CIITA-mediated gene regulation versus binding. These data therefore define the CIITA regulome in B cells and establish sequence specificities that predict activity for an essential regulator of the adaptive immune response.
Jimenez-Rondan F, Ruggiero C, Riva A, Yu F, Stafford L, Cross T Proc Natl Acad Sci U S A. 2025; 122(1):e2422321121.
PMID: 39793074 PMC: 11725848. DOI: 10.1073/pnas.2422321121.
A Ménage à trois: NLRC5, immunity, and metabolism.
Brunschwiler F, Nakka S, Guerra J, Guarda G Front Immunol. 2024; 15:1426620.
PMID: 39035010 PMC: 11257985. DOI: 10.3389/fimmu.2024.1426620.
Qiu Z, Khalife J, Ethiraj P, Jaafar C, Lin A, Holder K Sci Adv. 2024; 10(28):eadk2091.
PMID: 38996030 PMC: 11244530. DOI: 10.1126/sciadv.adk2091.
Engineering immune-evasive allogeneic cellular immunotherapies.
Martin K, Hammer Q, Perica K, Sadelain M, Malmberg K Nat Rev Immunol. 2024; 24(9):680-693.
PMID: 38658708 DOI: 10.1038/s41577-024-01022-8.
Glaser V, Flugel C, Kath J, Du W, Drosdek V, Franke C Genome Biol. 2023; 24(1):89.
PMID: 37095570 PMC: 10123993. DOI: 10.1186/s13059-023-02928-7.